Search
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalSynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Probiorinse
go.drugbank.com/drugs/DB15870Experimental[L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.
Pardoprunox
go.drugbank.com/drugs/DB12061InvestigationalPardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease.
Descartes-30
go.drugbank.com/drugs/DB16361InvestigationalDescartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.
Telcagepant
go.drugbank.com/drugs/DB12228InvestigationalIt is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. … CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain.
MLN3897
go.drugbank.com/drugs/DB06505ExperimentalMLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.
Allocetra
go.drugbank.com/drugs/DB16424InvestigationalWith infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals … Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune
Biricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
IN01
go.drugbank.com/drugs/DB16434ExperimentalOf note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.